JP2022526823A5 - - Google Patents

Info

Publication number
JP2022526823A5
JP2022526823A5 JP2021559727A JP2021559727A JP2022526823A5 JP 2022526823 A5 JP2022526823 A5 JP 2022526823A5 JP 2021559727 A JP2021559727 A JP 2021559727A JP 2021559727 A JP2021559727 A JP 2021559727A JP 2022526823 A5 JP2022526823 A5 JP 2022526823A5
Authority
JP
Japan
Application number
JP2021559727A
Other languages
Japanese (ja)
Other versions
JP2022526823A (ja
JPWO2020210698A5 (https=
JP7571044B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027764 external-priority patent/WO2020210698A1/en
Publication of JP2022526823A publication Critical patent/JP2022526823A/ja
Publication of JPWO2020210698A5 publication Critical patent/JPWO2020210698A5/ja
Publication of JP2022526823A5 publication Critical patent/JP2022526823A5/ja
Priority to JP2024176952A priority Critical patent/JP2025016496A/ja
Application granted granted Critical
Publication of JP7571044B2 publication Critical patent/JP7571044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559727A 2019-04-10 2020-04-10 リソソーム障害のための遺伝子療法 Active JP7571044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176952A JP2025016496A (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962831846P 2019-04-10 2019-04-10
US62/831,846 2019-04-10
US201962934450P 2019-11-12 2019-11-12
US62/934,450 2019-11-12
US201962954089P 2019-12-27 2019-12-27
US62/954,089 2019-12-27
US202062960471P 2020-01-13 2020-01-13
US62/960,471 2020-01-13
US202062988665P 2020-03-12 2020-03-12
US62/988,665 2020-03-12
PCT/US2020/027764 WO2020210698A1 (en) 2019-04-10 2020-04-10 Gene therapies for lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176952A Division JP2025016496A (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Publications (4)

Publication Number Publication Date
JP2022526823A JP2022526823A (ja) 2022-05-26
JPWO2020210698A5 JPWO2020210698A5 (https=) 2024-01-19
JP2022526823A5 true JP2022526823A5 (https=) 2024-01-19
JP7571044B2 JP7571044B2 (ja) 2024-10-22

Family

ID=70554180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559727A Active JP7571044B2 (ja) 2019-04-10 2020-04-10 リソソーム障害のための遺伝子療法
JP2024176952A Pending JP2025016496A (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176952A Pending JP2025016496A (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Country Status (20)

Country Link
US (2) US11999974B2 (https=)
EP (2) EP3953377B1 (https=)
JP (2) JP7571044B2 (https=)
KR (1) KR20210150486A (https=)
CN (1) CN114174324A (https=)
AU (2) AU2020273182B2 (https=)
BR (1) BR112021020183A2 (https=)
CA (1) CA3136004A1 (https=)
DK (1) DK3953377T3 (https=)
ES (1) ES3055985T3 (https=)
FI (1) FI3953377T3 (https=)
HR (1) HRP20251506T1 (https=)
IL (1) IL286903A (https=)
LT (1) LT3953377T (https=)
MX (1) MX2021011958A (https=)
PL (1) PL3953377T3 (https=)
PT (1) PT3953377T (https=)
RS (1) RS67476B1 (https=)
SI (1) SI3953377T1 (https=)
WO (1) WO2020210698A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
BR112020006671A2 (pt) 2017-10-03 2020-12-01 Prevail Therapeutics, Inc. terapias genéticas para distúrbios lisossômicos
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
PL3953377T3 (pl) 2019-04-10 2026-02-16 Prevail Therapeutics, Inc. Terapie genowe zaburzeń lizosomalnych
US20230346979A1 (en) * 2020-08-10 2023-11-02 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders
WO2023202637A1 (en) 2022-04-19 2023-10-26 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating neurodegenerative disorders
KR20250131772A (ko) * 2022-11-13 2025-09-03 알렉시온 파마 인터내셔널 오퍼레이션즈 리미티드 전두측두엽 치매에 대한 유전자 요법
EP4669361A2 (en) * 2023-02-24 2025-12-31 The Board of Trustees of the Leland Stanford Junior University BMP SYNTHASE ACTIVATORS AND INHIBITORS
WO2025251041A1 (en) * 2024-05-31 2025-12-04 Bluerock Therapeutics Lp METHODS AND COMPOSITIONS FOR TREATING PROGRANULIN DEFICIENCIES USING iPSC-DERIVED CELLS

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538119B2 (en) 1997-11-18 2003-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
AU2001290984A1 (en) 2000-09-18 2002-04-02 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
AU2002359284A1 (en) * 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US20030133924A1 (en) 2001-12-21 2003-07-17 Novazyme Pharmaceuticals, Inc. Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
AU2003221733A1 (en) 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
EP2687223B2 (en) 2006-05-30 2024-11-20 Mayo Foundation For Medical Education And Research Detecting and treating dementia
CA2653974A1 (en) 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
WO2007146046A2 (en) 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
ES2385679T3 (es) 2006-08-24 2012-07-30 Virovek, Inc. Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
WO2009079399A2 (en) 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
WO2009120978A2 (en) 2008-03-27 2009-10-01 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
US20150352185A1 (en) 2010-11-16 2015-12-10 Denis G. Kay Method for increasing neprilysin expression and activity
JP2016503405A (ja) 2012-11-05 2016-02-04 ジェンザイム・コーポレーション タンパク質症を処置するための組成物および方法
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
WO2016025523A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
WO2016081927A2 (en) 2014-11-21 2016-05-26 University Of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors
EP3292206B8 (en) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
PL3411484T3 (pl) 2016-02-05 2024-02-19 Emory University Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego
WO2017151884A1 (en) 2016-03-02 2017-09-08 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia
WO2017178826A1 (en) * 2016-04-14 2017-10-19 The University Of Liverpool Diagnosing acute bacterial meningitis
KR20230079511A (ko) 2016-04-21 2023-06-07 바이로베크 인코포레이티드 곤충 세포에서의 aav 생산, 및 이를 위한 방법 및 조성물
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
BR112020006671A2 (pt) 2017-10-03 2020-12-01 Prevail Therapeutics, Inc. terapias genéticas para distúrbios lisossômicos
EP3692075A4 (en) 2017-10-03 2022-02-09 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
AU2018354195A1 (en) 2017-10-23 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
MX2020004830A (es) * 2017-11-08 2020-11-11 Avexis Inc Medios y metodo para preparar vectores virales y usos de los mismos.
PL3953377T3 (pl) 2019-04-10 2026-02-16 Prevail Therapeutics, Inc. Terapie genowe zaburzeń lizosomalnych
CA3134841A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CA3136117A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
US20230346979A1 (en) 2020-08-10 2023-11-02 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders

Similar Documents

Publication Publication Date Title
JP2023537904A5 (https=)
JP2022526823A5 (https=)
CL2025004153A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso.
BR102021010467A2 (https=)
CN305529293S (https=)
CN305536342S (https=)
CN305534498S (https=)
CN305533942S (https=)
CN305532611S (https=)
CN305530572S (https=)
CN305528335S (https=)
CN306352899S (https=)
CN306348407S (https=)
CN306347795S (https=)
CN306347328S (https=)
CN306346237S (https=)
CN306343276S (https=)
CN306332720S (https=)
CN306331331S (https=)
CN306330646S (https=)
CN306328147S (https=)
CN306326830S (https=)
CN306325898S (https=)
CN306325222S (https=)
CN306324026S (https=)